The aim of the present study was to evaluate the effect of latanoprost monotherapy on the aqueous humour concentrations of TGF-beta1, MMP-2, TIMP-2, MMP-9 and gelatinolytic activity in patients treated for exfoliative glaucoma (XFG). Aqueous samples from 50 XFG patients treated with latanoprost and 50 age-matched XFG patients treated with timolol were collected during phacoemulsification cataract surgery. The concentrations of TGF-beta1, MMP-2, TIMP-2, MMP-9 and gelatinase activity were determined by commercial immunoassays. The mean active TGF-beta1 concentration in the aqueous was significantly lower in XFG patients treated with latanoprost compared with those treated with timolol (3.1 +/- 0.65 vs 13.4 +/- 1.5 pg ml(-1)); (P = 0.0014). The mean total MMP-2 concentration was lower in latanoprost treated patients (31.75 +/- 3.8 vs 81.5 +/- 7.2 ng ml(-1)); (P < 0.0001). The TIMP-2 concentration was also lower in XFG-latanoprost treated patients (73.8 +/- 6.81 vs 101.28 +/- 7.29 ng ml(-1)); (P = 0.0096). Latanoprost monotherapy has a marked effect on the aqueous concentration of TGF-beta1, MMP-2 and TIMP-2 in XFG patients. A better understanding of its effect on the pathobiology of the disease may lead to its earlier use in the disease process to prevent progression from XFS to XFG.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exer.2005.07.004DOI Listing

Publication Analysis

Top Keywords

patients treated
16
xfg patients
16
tgf-beta1 mmp-2
12
mmp-2 timp-2
12
aqueous humour
8
patients
8
exfoliative glaucoma
8
latanoprost monotherapy
8
concentrations tgf-beta1
8
timp-2 mmp-9
8

Similar Publications

Atopic dermatitis is a chronic inflammatory skin disease associated with immune dysregulation, particularly overexpression of T helper 2 cytokines. Cytotoxic T lymphocyte-associated antigen 4 deficiency, a primary immune disorder, can exacerbate atopic dermatitis. Dupilumab, an IL-4 and IL-13 receptor antagonist, has demonstrated efficacy in controlling severe, recalcitrant atopic dermatitis by mitigating T helper 2-driven inflammation.

View Article and Find Full Text PDF

Introduction: This paper examines the use of local antibiotic therapy in one-stage septic revision surgery for late periprosthetic joint infections (PJIs). This case study suggests that morselized bone allografts impregnated with antibiotics in powder form are a preferable alternative to polymethyl methacrylate (PMMA) because they can generate higher local antibiotic concentrations. Current research also recommends using vancomycin and aminoglycosides as the preferred choice of antibiotics, as they may have low diffusion in tissues when administered intravenously, but are effective when administered locally.

View Article and Find Full Text PDF

The first case of alveolar echinococcosis from southern Croatia: progressive course of the disease in an immunocompromised patient.

Germs

September 2024

MD, PhD, Infectious Diseases Department, University Hospital of Split, HR-21000 Split, Croatia, and University of Split School of Medicine, HR-21000 Split, Croatia, and University Department of Health Studies of the University of Split, HR-21000 Split, Croatia.

Introduction: Alveolar echinococcosis is one of the most pathogenic zoonoses caused by the larval forms of . It is endemic in central Europe, but from 2001 to 2018, eight European countries reported their first cases of alveolar echinococcosis. These numbers testify to unprecedented spread of the infection.

View Article and Find Full Text PDF

Introduction: Mobilization protocols are safe and feasible for critically ill pediatric patients in the intensive care unit (ICU), but barriers exist to sustainability. This study described a focused early mobility protocol, sustained over 5 years, which is on time for therapy consults and patient mobilization at a single institution.

Methods: A formal ICU mobility protocol was implemented as part of a unit-wide ICU liberation bundle.

View Article and Find Full Text PDF

The aim of the present study was to investigate the efficacy and safety of anlotinib combined with vinorelbine (NVB) as a second-line treatment for elderly patients with advanced squamous cell lung carcinoma (SqCLC). The present retrospective analysis included 48 elderly patients (aged ≥65 years) diagnosed with advanced SqCLC who received anlotinib in combination with NVB as a second-line therapy between January 2021 and December 2023. The primary endpoints assessed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety profile.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!